Nanobiotix (France) Top Management

NANO Stock  EUR 3.45  0.11  3.29%   
Nanobiotix employs about 103 people. The company is managed by 10 executives with a total tenure of roughly 241 years, averaging almost 24.0 years of service per executive, having 10.3 employees per reported executive. Analysis of Nanobiotix's management performance can provide insight into the company performance.
Sarah Gaubert  Insider
Head Department
Elsa Borghi  Insider
Head Discovery
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nanobiotix SA. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Nanobiotix Stock refer to our How to Trade Nanobiotix Stock guide.

Nanobiotix Management Team Effectiveness

The company has return on total asset (ROA) of (0.2916) % which means that it has lost $0.2916 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.9869) %, meaning that it generated substantial loss on money invested by shareholders. Nanobiotix's management efficiency ratios could be used to measure how well Nanobiotix manages its routine affairs as well as how well it operates its assets and liabilities.

Nanobiotix Workforce Comparison

Nanobiotix SA is considered to be number one stock in number of employees category among its peers. The total workforce of Drug Manufacturers - Major industry is now estimated at about 854. Nanobiotix retains roughly 103 in number of employees claiming about 12% of equities under Drug Manufacturers - Major industry.

Nanobiotix SA Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Nanobiotix SA Price Series Summation is a cross summation of Nanobiotix price series and its benchmark/peer.

Nanobiotix Notable Stakeholders

A Nanobiotix stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nanobiotix often face trade-offs trying to please all of them. Nanobiotix's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nanobiotix's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Sarah GaubertHead DepartmentProfile
Elsa BorghiHead DiscoveryProfile
Brandon OwensVP CommunicationProfile
Earl BergeyCoFounderProfile
Kathryn McNeilVP RelationsProfile
AnneJuliette MAChief BoardProfile
Bart RhijnCFO BoardProfile
Pr PrasadCoFounder BoardProfile
Alain DostieChief OfficerProfile
Laurent LevyPres CoFounderProfile

About Nanobiotix Management Performance

The success or failure of an entity such as Nanobiotix SA often depends on how effective the management is. Nanobiotix management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nanobiotix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nanobiotix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Nanobiotix SA, a late stage clinical company, develops and sells nanomedicine for the treatment of cancer worldwide. Nanobiotix SA was incorporated in 2003 and is headquartered in Paris, France. NANOBIOTIX operates under Drug Manufacturers - Major classification in France and is traded on Paris Stock Exchange. It employs 102 people.
Please note, the presentation of Nanobiotix's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nanobiotix's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nanobiotix's management manipulating its earnings.

Nanobiotix Workforce Analysis

Traditionally, organizations such as Nanobiotix use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nanobiotix within its industry.

Nanobiotix Manpower Efficiency

Return on Nanobiotix Manpower

Revenue Per Employee97.09
Revenue Per Executive1000
Net Loss Per Employee456.3K
Net Loss Per Executive4.7M
Working Capital Per Employee155.3K
Working Capital Per Executive1.6M

Complementary Tools for Nanobiotix Stock analysis

When running Nanobiotix's price analysis, check to measure Nanobiotix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nanobiotix is operating at the current time. Most of Nanobiotix's value examination focuses on studying past and present price action to predict the probability of Nanobiotix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nanobiotix's price. Additionally, you may evaluate how the addition of Nanobiotix to your portfolios can decrease your overall portfolio volatility.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope